文献速递肿瘤 PET/CT

PSMA PET/CT在前列腺癌生化复发治疗计划中的高影响:叙述性文献综述

Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature.
PubMed 文献 · J Nucl Med · 2019-03-08

该叙述性综述检索Medline、Embase、Web of Science、Google Scholar和Cochrane Central,纳入12篇报告PSMA PET对前列腺癌生化复发(BCR)患者治疗计划影响的研究。综述共涉及1,346例患者,PSMA PET/CT对治疗管理的影响在30%至76%之间,约半数患者出现治疗计划调整,低PSA(<0.5 ng/mL)患者也可检出常规影像无法发现的阳性病灶。

要点

  • PSMA PET/CT对BCR患者治疗管理的影响为30%-76%,约半数患者调整治疗计划。
  • 32%-67%的患者出现分期上调,低PSA(<0.5 ng/mL)也可检出阳性病灶。
  • 重要治疗调整包括避免全身治疗(17%-40%)和PET导向局部治疗(≤60%)。

核心结论

  • PSMA显像在BCR患者中具有高临床影响,约半数患者出现原始治疗计划调整。
  • 检出BCR复发可避免不必要的毒性并实现个体化治疗。

研究设计与样本

  • 叙述性文献综述,检索Medline、Embase、Web of Science、Google Scholar和Cochrane Central。
  • 纳入12篇报告PSMA PET对BCR前列腺癌患者治疗计划影响的研究,共1,346例患者。

主要发现

  • 所有纳入研究均强调PSMA PET图像对BCR前列腺癌患者治疗管理的影响。
  • PSMA PET/CT对治疗管理的影响在1,346例患者中为30%-76%。
  • 32%-67%的患者报告分期上调。
  • 低PSA值(<0.5 ng/mL)患者也显示阳性病灶,常规影像技术无法检出。
  • 重要治疗计划修改包括避免全身治疗(17%-40%)和PET导向局部治疗(≤60%的患者)。

临床怎么用

  • PSMA PET/CT可用于BCR前列腺癌患者的治疗计划制定,支持个体化治疗决策。
  • 对低PSA(<0.5 ng/mL)的BCR患者,PSMA PET/CT可检出常规影像无法发现的病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga- and 18F-labeled prostate-specific membrane antigen (PSMA) molecules have created new opportunities for the unmet diagnostic needs in prostate cancer. The purpose of this article is to give an overview of studies that have examined the role of PSMA PET in treatment planning for prostate cancer patients with biochemical recurrence (BCR). Methods: Medline, Embase, Web of Science, Google Scholar, and Cochrane Central were searched for relevant articles. After excluding the articles that did not fulfill the required criteria, we included in this review 12 publications that reported the impact of PSMA PET on the treatment plan for prostate cancer patients with BCR. Results: All studies in our review emphasized the impact of PSMA PET images on therapy management in prostate cancer patients with BCR. Overall, the impact of PSMA PET/CT on therapy management varied between 30% and 76% among the 1,346 patients included in the review. Upstaging was reported in 32%-67% of the patients. Patients with low prostate-specific antigen values (<0.5 ng/mL) also demonstrated positive lesions, which could not have been detected by means of conventional imaging techniques. Important modifications to the original treatment plan included avoidance of systemic therapy (17%-40%) and PET-directed local therapy (in ≤60% of the patients). Conclusion: PSMA imaging demonstrated a high clinical impact in patients with BCR, with modifications to the original treatment plan occurring among half the patients. Detecting recurrence in BCR can prevent unnecessary toxicity and lead to individualized therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ekmekcioglu Ö, Busstra M, Klass ND, et al. Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature. J Nucl Med. 2019. PMID: 30850500. doi:10.2967/jnumed.118.222885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。